Fulcrum halts losmapimod development by June Kinoshita This morning, we received news Fulcrum has decided to halt its development of losmapimod (see press release below). Fulcrum’s decision was based on… Read More »
Fulcrum halts losmapimod development
A note to our families from CEO Mark Stone
A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore,… Read More »
Advocating for Change on Capitol Hill
A Day of Impact in Washington, D.C. On May 8th, the FSHD Society held its first-ever Day on Capitol Hill in Washington, D.C. This milestone in our advocacy efforts brought… Read More »
FSHD Representation in Film Fest Favorite ‘Good Bad Things’
Good Bad Things breaks barriers and earns accolades by Erin Saxon, FSHD Society In August, we shared exciting news about Good Bad Things, a film that promised to challenge perceptions… Read More »
Honoring Rare Disease Day: The Power of Collaboration
Fulcrum and the FSHD Society Reflect on Partnership at Advocacy Event On February 28th, Fulcrum Therapeutics hosted a Rare Disease Day Advocacy Event at their headquarters in Cambridge, MA. This… Read More »